Transgene SA (0OCQ.L)
| Previous close | 1.1120 |
| Open | 1.1140 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.1140 - 1.1140 |
| 52-week range | 1.0450 - 2.2950 |
| Volume | |
| Avg. volume | 520 |
| Market cap | 69.484M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings date | 24 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTransgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will jointly present a poster on initial clinical results from the Phase I part of t
Globe NewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024
Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2024, the following resources were managed through the liquidity account: 338,789 shares€ 94,328.20 In the first half of 2024, it was negotiated a total of: Purchases204,900 shares€ 248,651894 market transactionsSales169,972 shares€ 217,858769 market transactions It is recalled that: as of December 31, 2023, the following resources were managed through the liquidity account: 303,861 shares€ 125,121 at the
- GlobeNewswire
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announces that the first patient has been enrolled in the Phase II part of t
